A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Clinical trial NCT05585320 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05585320
Sponsor: Immuneering Corporation
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Pancreatic Adenocarcinoma Malignant Melanoma (Cutaneous)Non-small Cell Lung Cancer (NSCLC)

Start date: 2022-10-31
Primary completion: 2026-06-01
Enrollment: 209

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.